Therapeutic development of a novel EphA4 antagonist for spinal cord injuries [ 2011 - 2014 ]

Research Grant

Researchers: Prof Perry Bartlett (Principal investigator) ,  E/Pr Andrew Boyd

Brief description Spinal cord injuries impose a significant burden on patients and their carers. At present, there are no treatments for spinal cord injury that provide functional improvement. This research program will develop a novel therapeutic molecule, EphA4-Fc, which promotes axonal regeneration and delivers significant functional improvement. We will determine the most effective protocol for EphA4-Fc administration and the physiological and functional outcomes of these treatment regimes.

Funding Amount $AUD 687,105.65

Funding Scheme NHMRC Development Grants

Notes Development Grant